SOHM, Inc. Announces the Appointment of Dr. Vivek Wayse to the Advisory Board as Medical Advisor
CHINO HILLS, CA / May 25, 2022 / SOHM, Inc. (OTC PINK: SHMN), a Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that it has signed an engagement agreement with Dr. Vivek Wayse to serve on the Advisory Board as Medical Advisor offering his expertise in strategy and business development.
Mr. Baron Night, President and CEO of SOHM Inc. said, “Dr. Wayse is an internationally known physician specializing in patented innovative and scientifically supported nutritional supplements for all consumers.” Night continued, “SOHM is extraordinarily proud and pleased to make this announcement as Dr. Wayse’s appointment brings a new line of patented products to our already extensive nutraceutical offering.”
Dr. Vivek Wayse is the founder and director of Nutri International established in 2007. Nutri International provides nutritional supplements that have been proven to be effective for the overall well-being and health of consumers around the world. Nutri International has a team of nutrition formulation specialists and a manufacturing base that has been developing and producing dietary supplements for over 15 years.
Included in Dr. Wayse’s extensive list of credentials is a line of publications and patents including the following granted patents:
1. A liquid colostrum composition and method of making the same application;
Status- Patent Granted – Patent No- 364069;
2. Emulsification process of omega-3 fatty acids with fruit pulp for palatable test and less odor;
Status- Patent Granted – Patent No- 346093; and
3. A vertical flow Immunoassay Device for Detection of Snake Envenomation;
Status- Patent Granted – Patent No- 365766.
Dr. Vivek Wayse stated, “Providing quality health care to all people around the world and advancing health equity is a shared priority for me and SOHM. I am delighted to join Mr. Night and his team of dedicated healthcare professionals, and I look forward to bringing my unique perspective to their business development and expansion strategy.”
SOHM, Inc. looks forward to announcing its line of products with valuation projections in association with Dr. Wayse in the weeks ahead.
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India as well as has strategic alliances with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact: